Get the Stockscreener App
15.68
0.77%
0.12
Q 32 Bio Inc stock is traded at $15.68, with a volume of 387.08K.
It is up +0.77% in the last 24 hours and up +23.08% over the past month.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
See More
Previous Close:
$15.56
Open:
$15.73
24h Volume:
387.08K
Relative Volume:
0.28
Market Cap:
$465.83M
Revenue:
$53.74M
Net Income/Loss:
$33.24M
P/E Ratio:
5.8877
EPS:
2.6632
Net Cash Flow:
$-27.40M
1W Performance:
+3.50%
1M Performance:
+23.08%
6M Performance:
+304.12%
1Y Performance:
+606.31%
1-Day Range:
$15.00
$15.99
1-Week Range:
$14.39
$16.61
52-Week Range:
$1.5685
$23.57
Q 32 Bio Inc Stock (QTTB) Company Profile
Name
Q 32 Bio Inc
Sector
Industry
Phone
781-999-0232
Address
830 WINTER STREET, WALTHAM
Compare QTTB vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QTTB
Q 32 Bio Inc
|
15.68 | 451.87M | 53.74M | 33.24M | -27.40M | 2.6632 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Q 32 Bio Inc Stock (QTTB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | H.C. Wainwright | Buy |
| Feb-11-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-11-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-11-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-11-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-24-24 | Initiated | Raymond James | Strong Buy |
| Sep-11-24 | Initiated | Wells Fargo | Overweight |
| Jun-17-24 | Initiated | Guggenheim | Buy |
| May-21-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Piper Sandler | Overweight |
| Jul-28-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-22-22 | Reiterated | BTIG Research | Neutral |
| Feb-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-22-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-02-21 | Initiated | Stifel | Hold |
| Dec-14-20 | Resumed | H.C. Wainwright | Buy |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-16-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-24-20 | Initiated | Chardan Capital Markets | Buy |
| Nov-01-19 | Initiated | Oppenheimer | Perform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
View All
Q 32 Bio Inc Stock (QTTB) Latest News
H.C. Wainwright raises Q32 Bio stock price target to $36 on alopecia drug outlook - Investing.com
Q32 Bio Inc (QTTB) Balance Sheet - TradingKey
Q32 Bio Inc (QTTB) Income Statement - TradingKey
Q32 Bio Inc (QTTB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Q32 Bio Inc (QTTB) Cash Flow - TradingKey
QTTB|Q32 Bio Inc|Price:15.060|Chg%:-0.150 - TradingKey
QTTB|Q32 Bio Inc|Price:15.140|Chg%:-0.010 - TradingKey
Q32 Bio Inc (QTTB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Q32 Bio Inc (QTTB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Q32 Bio Inc (QTTB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Q32 Bio Inc (QTTB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Q32 Bio Inc (QTTB) Institutional Confidence - TradingKey
Q32 Bio Inc. (QTTB) Stock Price, News, Quote & History - Yahoo! Finance Canada
Q32 Bio Inc (NASDAQ: QTTB) Stock Price, News & Analysis - Kalkine
Q32 Bio Inc Revenue Breakdown – DUS:DB0 - TradingView
Q32 Bio Inc (QTTB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Q32 Bio (QTTB) awards 10,826 stock options to director - Stock Titan
Q32 Bio (QTTB) corrects director’s 10,826 stock option award in Form 4/A - Stock Titan
Stock option grant for Q32 Bio Inc. (QTTB) director corrects prior award - Stock Titan
Q32 Bio Inc. (QTTB) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Form 4 Q32 Bio Inc For: 21 July By Investing.com - Investing.com Canada
Form 13D/A Q32 Bio Inc. For: 21 July By Investing.com - Investing.com Canada
OrbiMed reports 13.9% Q32 Bio ownership and 45-day lock-up (QTTB) - Stock Titan
Are You Looking for a Top Momentum Pick? Why Q32 Bio (QTTB) is a Great Choice - Yahoo Finance
Form S-3 Q32 Bio Inc For: 17 July By Investing.com - Investing.com Canada
Q32 Bio files prospectus for offer and resale of 6.875M shares - scanx.trade
Q32 Bio (Nasdaq: QTTB) files to register 6.9M shares for resale - Stock Titan
Q32 Bio: Bempikibart's Progress Keeps Me Bullish (NASDAQ:QTTB) - Seeking Alpha
Boxer Capital Management, LLC Acquires Significant Stake in Q32 Bio Inc - GuruFocus
Why is Q32 Bio stock falling Wednesday? - MSN
Q32 Bio Inc. Announces $300 Million Public Offering of Common Stock and Pre-Funded Warrants – Underwriting Agreement Details and Legal Opinions Included – Minichart - Minichart
Form 424B5 Q32 Bio Inc For: 15 July By Investing.com - Investing.com Nigeria
Q32 Bio Enters Underwriting for $18.25 Offering, Net Proceeds ~$188M; Option Lifts to ~$216M - TradingView
Q32 Bio (Nasdaq: QTTB) raises $187.6M in stock and pre-funded warrant deal - Stock Titan
Ericsson, Q32 Bio and other big stocks moving lower in Tuesday’s pre-market session - MSN
Why Is Q32 Bio Stock Falling Wednesday? - Benzinga
Ericsson, Q32 Bio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Sahm
Q32 Bio prices $200M public offering, shares fall - scanx.trade
Q32 Bio Prices $200 Million Share Sale to Accelerate Alopecia Areata Drug Development - finance.biggo.com
Q32 Bio prices $200M public offering to fund al... - Pluang
Q32 Bio Expects $200M Offering to Support Bempikibart Trials - Stock Titan
Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants - PR Newswire
$100 Invested In Q32 Bio 5 Years Ago Would Be Worth This Much Today - Benzinga
Q32 Bio Reports Positive Phase 2a Results for Bempikibart in Severe Alopecia Areata, Plans Pivotal Programme - BioPharma APAC
Why Q32 Bio Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket - Sahm
Q32 Bio (QTTB) After Positive Trial Data Is It A Buy Or Already Fairly Valued - Yahoo Finance
Q32 Bio delivers 23.91% average annual return over five years - scanx.trade
Mizuho raises Q32 Bio stock price target on alopecia drug data - Investing.com UK
Why Q32 Bio Stock Skyrocketed Today - The Motley Fool
Q32 Bio reports positive bempikibart trial data in alopecia areata - scanx.trade
Q32’s bempikibart starts to differentiate from JAK inhibitors in alopecia - BioCentury
Q 32 Bio Inc Stock (QTTB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Q 32 Bio Inc Stock (QTTB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Xu Diyong | Director |
May 28 '26 |
Buy |
8.00 |
1,875,000 |
15,000,000 |
3,502,987 |
| ORBIMED ADVISORS LLC | Director |
May 28 '26 |
Buy |
8.00 |
1,875,000 |
15,000,000 |
3,502,987 |
| Kalowski Lee | CFO and President |
Feb 25 '26 |
Sale |
4.51 |
3,995 |
18,035 |
35,943 |
| Morrison Jodie Pope | CEO |
Feb 25 '26 |
Sale |
4.51 |
9,896 |
44,675 |
89,104 |
| Violette Shelia M. | Chief Scientific Officer |
Feb 25 '26 |
Sale |
4.51 |
2,815 |
12,708 |
55,569 |
| Morrison Jodie Pope | CEO |
Dec 02 '25 |
Sale |
3.46 |
22,506 |
77,871 |
99,000 |
| Kalowski Lee | CFO and President |
Dec 02 '25 |
Sale |
3.46 |
9,072 |
31,395 |
39,938 |
2.44%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):